Photo: Abbott
Nov. 16, 2026 — Abbott has received CE Mark for its CardioMEMS HERO Device reader, a next-generation technology designed to make daily remote heart failure monitoring easier and more convenient for patients across Europe, where at least 15 million people are living with heart failure.
Part of Abbott’s CardioMEMS HF System, HERO is a new component of the system and works with a small sensor implanted in the pulmonary artery to monitor pressure changes that can signal worsening heart failure, often before symptoms appear. The reader allows patients to transmit daily readings sent from the implanted sensor via the reader to their care teams, helping clinicians identify changes and adjust treatment earlier.
-
The CardioMEMS HERO reader is designed to improve the functionality and user friendliness of the CardioMEMS HF System; in the U.S., data show the system has demonstrated a 57% reduction in heart failure hospitalizations.
-
HERO is 60% lighter than the previous reader and is designed to fit into a carry-on suitcase, making daily monitoring more convenient at home or while traveling.
-
Integrated Wi-Fi and cellular connectivity allow patients to take and transmit readings virtually anywhere they have a signal, helping care teams stay informed between appointments.
CardioMEMS HERO
“The CE Mark for CardioMEMS HERO is an important milestone in bringing more convenient heart failure monitoring to patients in approved markets across Europe.," said Finn Gustafsson, M.D., Ph.D., chief medical officer and divisional vice president of Abbott’s heart failure business. "With a smaller, more portable reader, we’re making it easier for patients to incorporate daily monitoring into their lives, while giving care teams the information they need to recognize changes early and intervene before symptoms worsen to help prevent heart failure hospitalizations.”
The European approval marks another step in Abbott’s continued advancement of the CardioMEMS HF System. Abbott recently received U.S. FDA approval for new CardioGuide HF App and Dynamic Treatment plan capabilities, giving patients greater visibility into their pulmonary artery pressure readings and helping them stay connected to their care teams.

November 13, 2026 
